<p>根據最近向證券交易委員會（SEC）披露的信息，Northern Trust Corp 在第四季度收購了 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免費報告）的一項新股份。該公司收購了 489,735 股該公司的股票，價值約為 162,000 美元。在最近的報告期末，Northern Trust Corp 擁有 Tonix Pharmaceuticals 約 26.20% 的股份。</p>
<p>獲取 <strong>Tonix Pharmaceuticals</strong> 警報：</p>
<ul>
<li>製藥狂潮：波動性點燃生物技術行業</li>
</ul>
<p>另外，Commonwealth Equity Services LLC 在第四季度購買了價值 40,000 美元的 Tonix Pharmaceuticals 新股份。對沖基金和其他機構投資者擁有該公司 82.26% 的股票。</p>
<h2>華爾街分析師的看法</h2>
<p>幾家研究公司最近對 TNXP 進行了評論。華爾街 Zen 在 5 月 30 日的研究報告中將 Tonix Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。Noble Financial 在 3 月 20 日的報告中重申了 “跑贏大盤” 的評級，並對 Tonix Pharmaceuticals 的股票設定了 70.00 美元的目標價。</p>
<ul>
<li>Tonix Pharmaceuticals 是下一個生物技術突破嗎？</li>
</ul>
<p><strong>獲取我們關於 Tonix Pharmaceuticals 的最新股票報告</strong></p>
<h2>Tonix Pharmaceuticals 的內部交易</h2>
<p>在相關消息中，首席執行官 Seth Lederman 於 5 月 15 日以每股 21.55 美元的平均價格收購了 4,000 股該公司的股票，總價值為 86,200.00 美元。購買完成後，首席執行官現在直接擁有 4,005 股該公司的股票，價值為 86,307.75 美元。這代表着他們持有的股票增加了 80,000.00%。該購買在向證券交易委員會提交的文件中披露，文件可通過此超鏈接訪問。公司內部人士擁有該公司 0.03% 的股票。</p>
<h2>Tonix Pharmaceuticals 股票上漲 6.3%</h2>
<p>TNXP 股票在週三開盤價為 40.45 美元。Tonix Pharmaceuticals Holding Corp. 的 52 周低點為 6.76 美元，52 周高點為 520.00 美元。該公司的 50 日移動平均線為 21.96 美元，200 日移動平均線為 22.55 美元。該公司的債務與股本比率為 0.07，速動比率為 2.81，流動比率為 3.33。該公司的市值為 2.963 億美金，市盈率為-0.01，貝塔值為 1.63。</p>
<p>Tonix Pharmaceuticals（NASDAQ:TNXP - 獲取免費報告）最近在 5 月 12 日發佈了其財報。該公司報告本季度每股收益為（2.84 美元），超出分析師一致預期的（3.23 美元）0.39 美元。Tonix Pharmaceuticals 的股本回報率為-163.95%，淨利潤率為-1,197.86%。該公司本季度的收入為 243 萬美元，而一致預期為 255 萬美元。作為一個整體，分析師預測 Tonix Pharmaceuticals Holding Corp. 本年度每股收益將為-1762.5。</p>
<h2>關於 Tonix Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>Tonix Pharmaceuticals Holding Corp. 是一家生物製藥公司，專注於開發、發現、商業化和許可治療人類疾病和減輕痛苦的療法。它市場銷售 Zembrace SymTouch 和 Tosymra，用於治療成人急性偏頭痛（有或沒有先兆）。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Tonix Pharmaceuticals</li>
<li>股息支付比率計算器</li>
<li>市場上最被做空的：2 家空頭頭寸超過 40% 的公司</li>
<li>動盪市場中的資產配置策略</li>
<li>Ollie’s 第一季度財報：好、壞及未來展望</li>
<li>比較和交易高市盈率股票</li>
<li>Rocket Lab 擴展到有效載荷：你應該關注嗎？</li>
</ul>
<p><strong>想看看其他對 TNXP 感興趣的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Tonix Pharmaceuticals 嗎？</h2>
<p>在考慮 Tonix Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Tonix Pharmaceuticals 並不在名單上。</p>
<p>雖然 Tonix Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

NTRS

Tonix 醫藥控股

<p>北方信託公司在第四季度收購了 489,735 股 Tonix Pharmaceuticals Holding Corp.（納斯達克代碼：TNXP），價值約為 162,000 美元，使其持股比例增加至 26.20%。英聯邦證券服務公司也購買了價值 40,000 美元的股份。分析師對 TNXP 的看法不一，華爾街 Zen 將其評級下調至 “賣出”，而諾布爾金融則維持 “跑贏大盤” 的評級，目標價為 70 美元。最近，Tonix 的股票上漲了 6.3%，市值為 2.963 億美元，報告的每股收益為-2.84，超出預期。該公司專注於開發人類疾病的治療藥物</p>

<p>Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 489,735 shares of the company's stock, valued at approximately $162,000. Northern Trust Corp owned about 26.20% of Tonix Pharmaceuticals at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根據最近向證券交易委員會（SEC）披露的信息，Northern Trust Corp 在第四季度收購了 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免費報告）的一項新股份。該公司收購了 489,735 股該公司的股票，價值約為 162,000 美元。在最近的報告期末，Northern Trust Corp 擁有 Tonix Pharmaceuticals 約 26.20% 的股份。</p>
</div><p>Get <strong>Tonix Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tonix Pharmaceuticals</strong> 警報：</p>
</div><ul>
<li>Pharma Frenzy: Volatility Ignites Biotech Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>製藥狂潮：波動性點燃生物技術行業</li>
</ul>
</div><p>Separately, Commonwealth Equity Services LLC purchased a new stake in shares of Tonix Pharmaceuticals during the fourth quarter valued at $40,000. Hedge funds and other institutional investors own 82.26% of the company's stock.</p>
<div class="lb-trans"><p>另外，Commonwealth Equity Services LLC 在第四季度購買了價值 40,000 美元的 Tonix Pharmaceuticals 新股份。對沖基金和其他機構投資者擁有該公司 82.26% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師的看法</h2>
</div><p>Several research firms recently commented on TNXP. Wall Street Zen cut Tonix Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Friday, May 30th. Noble Financial reissued an &#34;outperform&#34; rating and issued a $70.00 target price on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.</p>
<div class="lb-trans"><p>幾家研究公司最近對 TNXP 進行了評論。華爾街 Zen 在 5 月 30 日的研究報告中將 Tonix Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。Noble Financial 在 3 月 20 日的報告中重申了 “跑贏大盤” 的評級，並對 Tonix Pharmaceuticals 的股票設定了 70.00 美元的目標價。</p>
</div><ul>
<li>Is Tonix Pharmaceuticals the Next Biotech Breakout?</li>
</ul>
<div class="lb-trans"><ul>
<li>Tonix Pharmaceuticals 是下一個生物技術突破嗎？</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on Tonix Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Tonix Pharmaceuticals 的最新股票報告</strong></p>
</div><h2>Insider Transactions at Tonix Pharmaceuticals</h2>
<div class="lb-trans"><h2>Tonix Pharmaceuticals 的內部交易</h2>
</div><p>In related news, CEO Seth Lederman acquired 4,000 shares of the firm's stock in a transaction dated Thursday, May 15th. The shares were purchased at an average price of $21.55 per share, with a total value of $86,200.00. Following the completion of the purchase, the chief executive officer now directly owns 4,005 shares of the company's stock, valued at $86,307.75. This represents a 80,000.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.03% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席執行官 Seth Lederman 於 5 月 15 日以每股 21.55 美元的平均價格收購了 4,000 股該公司的股票，總價值為 86,200.00 美元。購買完成後，首席執行官現在直接擁有 4,005 股該公司的股票，價值為 86,307.75 美元。這代表着他們持有的股票增加了 80,000.00%。該購買在向證券交易委員會提交的文件中披露，文件可通過此超鏈接訪問。公司內部人士擁有該公司 0.03% 的股票。</p>
</div><h2>Tonix Pharmaceuticals Stock Up 6.3%</h2>
<div class="lb-trans"><h2>Tonix Pharmaceuticals 股票上漲 6.3%</h2>
</div><p>TNXP stock opened at $40.45 on Wednesday. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $6.76 and a fifty-two week high of $520.00. The business's 50-day moving average is $21.96 and its two-hundred day moving average is $22.55. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market cap of $296.30 million, a price-to-earnings ratio of -0.01 and a beta of 1.63.</p>
<div class="lb-trans"><p>TNXP 股票在週三開盤價為 40.45 美元。Tonix Pharmaceuticals Holding Corp. 的 52 周低點為 6.76 美元，52 周高點為 520.00 美元。該公司的 50 日移動平均線為 21.96 美元，200 日移動平均線為 22.55 美元。該公司的債務與股本比率為 0.07，速動比率為 2.81，流動比率為 3.33。該公司的市值為 2.963 億美金，市盈率為-0.01，貝塔值為 1.63。</p>
</div><p>Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($2.84) earnings per share for the quarter, beating analysts' consensus estimates of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The company had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.55 million. As a group, analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.</p>
<div class="lb-trans"><p>Tonix Pharmaceuticals（NASDAQ:TNXP - 獲取免費報告）最近在 5 月 12 日發佈了其財報。該公司報告本季度每股收益為（2.84 美元），超出分析師一致預期的（3.23 美元）0.39 美元。Tonix Pharmaceuticals 的股本回報率為-163.95%，淨利潤率為-1,197.86%。該公司本季度的收入為 243 萬美元，而一致預期為 255 萬美元。作為一個整體，分析師預測 Tonix Pharmaceuticals Holding Corp. 本年度每股收益將為-1762.5。</p>
</div><h2>About Tonix Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Tonix Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.</p>
<div class="lb-trans"><p>Tonix Pharmaceuticals Holding Corp. 是一家生物製藥公司，專注於開發、發現、商業化和許可治療人類疾病和減輕痛苦的療法。它市場銷售 Zembrace SymTouch 和 Tosymra，用於治療成人急性偏頭痛（有或沒有先兆）。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Tonix Pharmaceuticals</li>
<li>Dividend Payout Ratio Calculator</li>
<li>Among the Market’s Most Shorted: 2 Firms With +40% Short Interest</li>
<li>Asset Allocation Strategies in Volatile Markets</li>
<li>Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>Rocket Lab Expands Into Payloads: Should You Be Paying Attention?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Tonix Pharmaceuticals</li>
<li>股息支付比率計算器</li>
<li>市場上最被做空的：2 家空頭頭寸超過 40% 的公司</li>
<li>動盪市場中的資產配置策略</li>
<li>Ollie’s 第一季度財報：好、壞及未來展望</li>
<li>比較和交易高市盈率股票</li>
<li>Rocket Lab 擴展到有效載荷：你應該關注嗎？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TNXP?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 TNXP 感興趣的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TNXP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tonix Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Tonix Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Tonix Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Tonix Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Tonix Pharmaceuticals 並不在名單上。</p>
</div><p>While Tonix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tonix Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Northern Trust Corp Acquires New Shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Northern Trust 公司收購了 Tonix 醫藥控股公司（NASDAQ:TNXP）的新股份